The Ethics of Continuing Placebo in SARS-CoV-2 Vaccine Trials

This Viewpoint proposes that prioritizing all placebo-group participants in coronavirus vaccine trials as vaccine first receivers could perpetuate health inequities and compromise the chance to learn from their participation, proposing instead to limit prioritization to placebo participants who…

Read the full article here

Related Articles